We Partner 4 Research

Eligibility

Eligible Ages

Over 18 Years

Eligible Sex

All

Accepts Healthy Volunteers

Yes

Criteria

Inclusion Criteria:

- NON-PATIENT: Participants must be an oncology healthcare provider (i.e., oncologist,
advanced practice provider, or oncology nurse)

- NON-PATIENT: Participants must have taken care of at least one patient randomized to
Arm B (CONCURxP) who had less than 85% adherence rate at 12 months as measured by
the WiseBag

- NON-PATIENT: Participant must speak English

- NON-PATIENT: Participant must be employed at an National Cancer Institute Community
Oncology Research Program (NCORP) site for at least 6 months

- NON-PATIENT: Participant must be able to provide informed consent to participate in
this study

- PATIENT STEP 0: Patient must be >= 18 years of age

- PATIENT STEP 0: Patient must be fluent in written and spoken English OR patient must
be fluent in written and spoken Spanish

- PATIENT STEP 0: Patient must present with new or established pathologically proven
hormone receptor (HR)+ HER2- metastatic breast cancer at the time of Step 0

- PATIENT STEP 0: Patient must have initiated any of the CKD4/6 inhibitors
(palbociclib or Ibrance, ribociclib or Kisqali, abemaciclib or Verzenio) within 30
days prior to consenting to Step 0 or have received a prescription order with stated
intent to initiate within 30 days following Step 0 consent

- NOTE: Patients who have been treated previously with anticancer treatments
other than CDK4/6 inhibitors are eligible

- NOTE: CDK4/6 inhibitors must be provided/supplied as a single agent blister
pack. If the medication is supplied as capsules in a pill bottle (e.g., Ibrance
capsules), patient is not eligible

- NOTE: Ribociclib (Kisqali) and abemaciclib (Verzenio) are only available in
blister packs. Palbociclib (Ibrance) is the only CDK4/6 inhibitor that might be
available in a capsule formulation. However, this is an outdated formulation
and is rarely prescribed as a new start. The format of ordered palbociclib can
be determined based on the prescription order

- PATIENT STEP 0: Patients must not have been previously treated with any of the
following CDK4/6 inhibitors: Palbociclib or Ibrance, ribociclib or Kisqali, and
abemaciclib or Verzenio

- PATIENT STEP 0: Patients must not already be enrolled in a therapeutic clinical
trial that monitors CDK4/6 inhibitors

- PATIENT STEP 0: Patient must confirm that they intend to receive their care or
monitoring at an NCORP site

- PATIENT STEP 0: Patient must have a personal mobile phone in which they are able and
willing to send and receive text messages

- NOTE: The restriction to those with mobile phone access with text messaging is
based on the primary intention of the study which involves the use of text
messaging to improve adherence

- PATIENT STEP 0: Patient must have an email address

- NOTE: The restriction to those with an email address is based on the primary
intention of the study which involves patients responding to questions
regarding their reasons for non-adherence after every missed dose to improve
adherence

- PATIENT STEP 0: Patient must have the ability to understand and the willingness to
sign a written informed consent document

- NOTE: Patients with impaired decision-making capacity (IDMC) who have a legally
authorized representative (LAR) or caregiver and/or family member available are
not eligible

- PATIENT STEP 0: Patient must not have an Eastern Cooperative Oncology Group (ECOG)
performance status >= 3 OR patient must not be deemed medically unable to
participate in the study by the study investigators or an oncology clinician (i.e.,
referral to hospice)

- PATIENT STEP 0: Patient must not be enrolled in other trials offering financial
assistance

- NOTE: Gift cards for survey completion, parking passes, or free medication
provided as part of therapeutic trials are not considered financial assistance

- PATIENT STEP 1: Patient must meet all the eligibility criteria for Step 0

- PATIENT STEP 1: Patient must have signed a written informed consent form

- PATIENT STEP 1: Patient must have completed baseline survey within 30 days of the
date of Step 0 Registration

- PATIENT STEP 1: Patients must have initiated their CDK 4/6 inhibitors within 30 days
of the date of Step 0 registration